Q-Linea
Labema Oy places its first ASTar order
Q-linea AB (publ) (OMX: QLINEA) today announces that the company has received an order for an ASTar System from its distribution partner in Finland and the Baltics, Labema Oy.
“Our partner, Labema Oy, is preparing for the first installation at a hospital who wants to understand how ASTar can improve their workflows and patient outcome,” said Thomas Fritz, CCO at Q-linea. “From an international perspective, the levels of antimicrobial resistance (AMR) are low in the Nordic countries. However, AMR is a global cross-border health threat, and rapid AST can have multiple positive impacts on patient outcomes.”
About ASTar Instrument and ASTar BC G- Kit
ASTar Instrument and ASTar BC G- Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.
ASTar Instrument and ASTar BC G- Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.
Datum | 2024-01-31, kl 09:52 |
Källa | MFN |
![](https://static.allaaktier.se/ads/hand-waving-2.png)